The 2025 BioUtah Life Sciences Awards will honor five recipients at the Mayer Brown Utah Life Sciences Summit on November 12, recognizing significant contributions to Utah's life sciences industry. These awards highlight the state's growing influence in healthcare innovation, with winners spanning academic research, medical device development, cancer treatment technology, and educational leadership.
Wesley Sundquist, PhD, Samuels Professor and Chair of the Department of Biochemistry at the University of Utah, receives recognition for his decades of HIV research that directly contributed to the U.S. Food and Drug Administration's approval of Lenacapavir in June 2025. This HIV prevention drug, developed by Gilead Sciences using Sundquist's findings on HIV assembly and replication, represents a major advancement in combating the global HIV epidemic. Sundquist's distinguished career includes numerous honors such as the Horwitz Prize for Biochemistry and inclusion on the TIME100 2025 list of most influential people.
Fred Lampropoulos, Executive Chairman of Merit Medical Systems, is honored for his leadership in building the South Jordan-based company since its formation in 1987. Under his guidance, Merit Medical Systems has grown to over $1.5 billion in revenue while securing more than 500 domestic and international patents for medical devices. Lampropoulos has expanded the company's operations to Texas, Virginia, and multiple international locations including Ireland, Mexico, and Singapore, while maintaining strong employee support through on-site medical clinics and community gardens.
Shawn Fojtik, CEO of Distal Access, is recognized for his entrepreneurial spirit and innovation across multiple medical technology companies. With over 100 combined issued and pending patents, Fojtik's contributions include cardiovascular angioplasty catheters, embolic liquids, thrombectomy systems, and electrophysiology mapping technologies that have achieved more than one million safe-patient uses. His technology developments have resulted in more than 10 successful exits to third-party companies that have commercialized his inventions.
Nusano, based in West Valley City, is awarded for developing a proprietary platform that produces more than 40 different radioisotopes for targeted cancer therapies. Their technology delivers precise, high-energy radiation directly to tumor cells while sparing healthy tissue, representing a significant advancement in cancer treatment. Nusano's work is attracting other life sciences companies to Utah, including Ratio Therapeutics and PharmaLogic, and building an innovation ecosystem that accelerates cancer research while creating jobs. More information about their approach can be found at utahlifesciencessummit.com.
University of Utah President Taylor Randall receives recognition for his partnership in advancing Utah's life sciences ecosystem through initiatives like the Life Sciences Workforce Initiative and the establishment of the University of Utah Venture Fund. His administration has focused on transforming university research into practical applications, including the completion of the James LeVoy Sorenson Center for Medical Innovation and the development of the University of Utah Eccles Health Campus in West Valley City. Randall's international collaboration efforts led to life sciences training programs funded by the Utah legislature in 2025.
These awards demonstrate Utah's expanding role in addressing critical healthcare challenges through scientific innovation, medical device development, and strategic workforce planning. The recognition of both established leaders and emerging companies underscores the state's comprehensive approach to life sciences advancement, with implications for patient care, economic development, and global health solutions.
